Lupus is a complex disease that affects different people in different ways. For this reason, it has been difficult to develop a single measure that takes into account several aspects of disease activity. Now, researchers are addressing that challenge with the new Lupus Multivariable Outcome Score Index (LuMOS 2.0). LuMOS was originally created to help measure the effectiveness of new therapies by evaluating clinically relevant responses to treatment in clinical trials. LuMOS 2.0 now offers an even more refined version of the original scoring system to help ensure relevant treatment outcome data is captured in clinical trials.
LuMOS 2.0 was developed with the aim of optimizing the sensitivity of the measurement. In the latest study, researchers used data from previous clinical trials to assess how well LuMOS 2.0 captured relevant changes in disease activity after treatment compared to the Systemic Lupus Erythematosus Responder Index-5 (SRI- 5), a different tool used to measure lupus disease activity and treatment response. The SRI-5 is a validated measure that is commonly used in lupus drug trials. The results showed that LuMOS 2.0 was better than SRI-5 at detecting drug treatment effects.
LuMOS 2.0 shows promise in providing drug developers and clinicians with a simple and even more robust outcome measure to better assess a drug’s effectiveness. A standardized model can help identify new effective treatments for lupus; however, further research is needed to fully validate the LuMOS 2.0 score index. Learn more about treatments being studied for lupus.
Read the study